PDCD10

Across TCGA pan-cancer cohorts, PDCD10 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PDCD10 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDCD10 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDCD10 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, COAD, and LSCC are the cancer types where PDCD10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.604	0.122	.004	26	view →
COAD	DFS	Median	IV	0.432	0.944	.012	6	view →
LSCC	OS	Median	All	0.826	0.898	.030	5	view →
GBM	DFS	Tertile	All	0.831	0.604	.012	2	view →
CCRCC	OS	Median	All	1.000	0.755	.041	1	view →
LUAD	OS	Median	II,III,IV	0.968	0.894	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PDCD10–PDAC (DFS)

Open the PDAC breakdown →